Differential response to donepezil in MRI subtypes of mild cognitive impairment

Differential response to donepezil in MRI subtypes of mild cognitive impairment

Abstract Background Donepezil is an approved therapy for the treatment of Alzheimer’s disease (AD). Results across clinical trials have been inconsistent, which may be explained by design-methodological issues, the pathophysiological heterogeneity of AD, and diversity of included study participants....

Full description

Bibliographic Details
Main Authors: Patricia Diaz-Galvan, Giulia Lorenzon, Rosaleena Mohanty, Gustav Mårtensson, Enrica Cavedo, Simone Lista, Andrea Vergallo, Kejal Kantarci, Harald Hampel, Bruno Dubois, Michel J. Grothe, Daniel Ferreira, Eric Westman
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Alzheimer’s Research & Therapy
Subjects:
Randomized controlled trial
Donepezil
Mild cognitive impairment
Heterogeneity
Subtypes
Alzheimer’s disease
Online Access:https://doi.org/10.1186/s13195-023-01253-2

Internet

https://doi.org/10.1186/s13195-023-01253-2

Similar Items